NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 1.8%. Evaxion Biotech expanded its collaboration with Merck regarding two preclinical vaccine candidates in a deal worth up to MUSD 592 per candidate as well as royalties on sales. Furthermore, Acarix raised MSEK 22.6, SynAct Pharma initiated a phase IIb study, and CS Medica provided additional IPO news.
6 of the 22 Danish biotech companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra and Phila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Acarix announces outcome of warrant exercise of series 3 (Link)
No news the past week
No news the past week
No news the past week
CS MEDICA A/S Update from CEO: Strategic Developments on CANNORDIC Planned IPO Milestones (Link)
No news the past week
Calls for an Extraordinary General Meeting regarding New Authorizations and Reduction of Share Capital in Preparation for Reverse Stock Split (Link)
Evaxion significantly expands vaccine development collaboration with MSD (Link)
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
SynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US (Link)
No news the past week
No news the past week
No news the past week
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL) (Link)
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 2.9%. Most notably, Evaxion entered into a deal with MSD (Merck & Co.) regarding two preclinical vaccine candidates. Evaxion will receive an upfront payment of MUSD 3.2 and up to MUSD 10 in 2025. If the company hits all milestones the potential value is MUSD 592 per candidate as well as royalties on net sales. Furthermore, Acarix raised MSEK 22.6 before issuance costs in an exercise of series 3 warrants, and SynAct initiated a phase IIb study with Resomelagon in the U.S. CS Medica also provided additional information regarding their CANNORDIC IPO at an initial valuation of more than twice the current market cap. of CS Medica.
Gubra continues to be the best-performing stock year-to-date with a return of 290%. Pila Pharma, Cessatech, Zealand Pharma, and CS Medica have also generated returns of over 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.8% to 67,11. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indexes in terms of performance. In the past 12 months, the KPHC index has underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by quite a lot.
Price charts for the KPHC, KPNGX, C25, and S30 index for the past twelve months
27-49% in weekly return for the Nordic healthcare stocks
XP Chemistries AB (49%) is a Swedish biotechnology company with patented technology for producing capsaicin from forest raw materials. Capsaicin is a fat-soluble, color- and odorless, waxy substance. Capsaicin is used today in most products, including animal feed, pest control, cosmetics, and medical products.
Level Bio (39%) is focused on developing patented technology enabling the identification of viruses and bacteria. Products are sold under several trademarks as well as through their own distribution to laboratories and research institutes.
Scibase Holding AB (27%) is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body’s skin tissue. The stock rose following a major sale of Nevisense, a leading skin barrier research tool, to the National Institutes of Health (NIH), one of the world’s foremost medical research centers and part of the US Department of Health and Human Services. This acts as a great validation of Scibase’s platform.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
